Project Grant R01HL188041
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $797K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $867,656 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to develop and apply comparative effectiveness evidence methods for evaluating medical therapies in heart failure with mildly reduced ejection fraction (HFMREF). The award funds completion of the largest echocardiography registry in the world and application of regression discontinuity...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital $747,256 under Cardiovascular Diseases Research (CFDA 93.837) on August 17, 2026, to investigate the role of METTL3 (a methyltransferase enzyme) in heart failure with preserved ejection fraction (HFpEF). The project addresses an unmet clinical need: no pharmacological therapy has been proven to improve survival in HFpEF, the most prevalent form of heart failure particularly among patients with metabolic...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $121,345 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026. The award funds development of positron emission tomography (PET) imaging of oxidized collagen as a biomarker for myocardial fibrosis in heart failure with preserved ejection fraction (HFpEF). The project focuses on targeted PET imaging probes that bind...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $736,411 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of neutrophil-derived resistin-like molecule G (RELMG) in arrhythmia pathogenesis and prevention. The research examines RELMG's mechanism of action and therapeutic potential in reducing ventricular tachycardia and atrial fibrillation following...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $1,579,554 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 10, 2025, to conduct multi-trait, multi-ancestry, and multi-omic genetic studies of chronic obstructive pulmonary disease (COPD) and asthma using data integrated across global biobanks. The work integrates genetic and phenotypic data from the All of Us Research Program,...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $2,401,048 for Project Grant R01HL184086 on September 1, 2026 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds GO MOMS PREDICT, a prospective study that develops and tests pregnancy-based cardiovascular disease risk assessment models to predict cardiovascular outcomes five years after delivery. The study leverages an existing...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 1, 2026, for whole genome sequence interpretation to identify new genes and mechanisms underlying coronary artery disease and familial hypercholesterolemia. The award funds research to improve genetic diagnostic yield for familial hypercholesterolemia, an inherited form of...
- The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease. The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $770,247 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define the mechanistic basis of airway metaplastic response through investigation of stem cell heterogeneity, YAP signaling, and EGFR signaling pathways. The research addresses the cellular source and molecular mechanisms governing squamous and mucous metaplasia—two...